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In the two-signal model of T cell activation, the outcome of antigen recognition is determined by the integra-
tion ofmultiple cues in the immunemicroenvironment. mTOR is an evolutionarily conserved PI3-kinase family
member that plays a central role in integrating environmental cues in the form of amino acids, energy, and
growth factors. Recently, an increasingly important role for mTOR in directing T cell activation and differen-
tiation has become apparent. Here we review recent findings demonstrating the ability of mTOR to interpret
signals in the immune microenvironment and program the generation of CD4+ effector versus regulatory
T cells, the generation of CD8+ effector versus memory cells, T cell trafficking, and T cell activation versus
anergy. The key theme to emerge from these studies is that the central role of mTOR provides a direct link
between T cell metabolism and function.Introduction
A central role for mTOR in regulating immune responses is
emerging. mTOR has been implicated in neutrophil, monocyte,
dendritic cell, B cell, gamma-delta, and alpha-beta T cell
function (Delgoffe and Powell, 2009; Mills and Jameson, 2009;
Weichhart and Saemann, 2009). This review focuses on recent
findings elucidating the ability of mTOR to regulate T cell differ-
entiation and activation. Specifically, observations demon-
strating the link between the unique metabolic requirements of
T cells and the ability of mTOR to integrate environmental cues
to direct T cell differentiation and function will be discussed.The Disassociation of Recognition and Function
in the Adaptive Immune Response
In the most primitive host defenses, recognition and function
occur nearly simultaneously (Braun et al., 1994). For example,
proteins produced by one strain of bacteria recognize receptors
and kill other strains of bacteria. As organisms became more
complex, the need for more sophisticated immune responses
evolved. Recognition of pathogen-associated molecular
patterns (PAMPs) by different receptors led to differential
signaling and responses (Janeway, 1989). For example, in
Drosophila PAMPs can lead to different responses depending
on whether the Toll or immune deficiency (IMD) pathway is
activated. Signaling via Toll pathways leads to the elaboration
of the antimicrobial protein attacin whereas IMD signaling leads
to the expression of drosomycin (Tanji and Ip, 2005). That is,
recognition of Toll leads to a distinct form of activation when
compared to activation of IMD. Still, recognition and activation
occur via a single signal or receptor.
The development of adaptive immune responses heralded the
disassociation of recognition and response. Antigen receptors
of adaptive responses are the products of stochastic mecha-
nisms of generating diversity. Whereas such receptors are char-
acterized by exquisite specificity, recognition of antigen does not
impart information in terms of what type of response should
ensue. Rather, this information is provided by accessory(‘‘second’’ or ‘‘third’’) signals (Curtsinger and Mescher, 2010;
Sharpe, 2009). That is, when a T cell receptor recognizes its
cognate peptide (for example ovalbumin peptide), there is
nothing about the recognition of ovalbumin that tells the T cell
whether to become a T helper 1 (Th1), Th2, Th17, or regulatory
cell. Likewise, this recognition does not instruct a differentiated
cell to become activated or anergic. Such instructions come
from the presence or absence of signals derived from the
environment that not only mediate early innate immunity but
qualitatively modulate adaptive immunity. As such, with this
increase in sophistication with respect to antigen recognition
came the necessity to develop a mechanism to integrate
environmental cues.The Mammalian Target of Rapamycin
as an Environmental Sensor
Rapamycin was originally identified as an antifungal compound
derived fromStreptomyces hygroscopicus, found in soil samples
collected from Easter Island (locally known as Rapa nui) (Dennis
et al., 1999). Although rapamycin was found to be a poor antibi-
otic, it did turn out to have potent immunosuppressive activity.
Initially, its immunosuppressive properties were ascribed to its
ability to inhibit cell proliferation. This was in contrast to another
macrolide antibiotic, Cyclosporine A (CSA), which suppresses
immune responses by inhibiting calcineurin and thereby block-
ing TCR signaling (Powell and Zheng, 2006).
Efforts to identify the mechanism by which rapamycin exerted
its effects led to the discovery of the Target of Rapamycin 1
(TOR1) and TOR2 in yeast and subsequently the mammalian
homolog, mTOR (also known as FKBP-rapamycin-associated
protein [FRAP], rapamycin and FKBP12 targets [RAFT]) (Schmel-
zle and Hall, 2000). Genetic and biochemical analysis of mTOR
revealed that it was a 289 kDa protein that had substantial
sequence homology with the phosphoinositide 3-kinase (PI3-
kinase) family. However, mTOR is not a lipid kinase but rather
a serine-threonine protein kinase. Interestingly, although in yeast
there are two separate TOR genes (TOR1 and TOR2), inImmunity 33, September 24, 2010 ª2010 Elsevier Inc. 301
Figure 1. mTOR Signaling for the Immunologist
Based on the review of Laplante and Sabatini (2009b), this figure is designed to be a ready reference for upstream and downstream signaling as well as the
components of mTORC1 and mTORC2. Details of mTORC1 and mTORC2 signaling pathways are described in the main text. Although the figure is not meant
to be exhaustive, we try to emphasize the connections between CD28 and IL-2R signaling with signals derived from leucine, oxygen, and energy. Note, blue lines
indicate signals upstreamofmTOR that ultimately lead to its activation. Orange lines depict upstream signals that lead to the inhibition of mTOR. Green lines show
downstream mTOR signaling that promotes a particular function, and red lines depict downstream inhibitory signals.
Immunity
Reviewmammalian cells mTOR is encoded as a single gene whose pro-
tein product signals via two distinct complexes (mTORC1 and
mTORC2). mTOR complex 1 (mTORC1) contains the scaffolding
protein regulatory-associated protein of mTOR (raptor) as well as
mammalian lethal with Sec13 protein 8 (mLST8), the proline-rich
Akt substrate 40 kDa (PRAS40), and DEP-domain-containing
mTOR-interacting protein (Deptor) (see Laplante and Sabatini,
2009b, for an up-to-date comprehensive review of mTOR sig-
naling). The secondmTOR signaling complex (mTORC2) consists
of mLST8, the scaffolding protein raptor-independent companion
of TOR (rictor), mSIN1 proteins, and the protein observed with
rictor (Protor) (Laplante and Sabatini, 2009b).
Evolutionarily conserved from yeast to man, mTOR integrates
environmental cues as a means of regulating cellular size,
growth, proliferation, survival, and metabolism (Guertin and
Sabatini, 2007). As such, it is not surprising that mTOR activation
can be regulated by diverse stimuli such as amino acid avail-
ability, oxygen, energy status, and growth factors. The upstream
signaling events that lead to the activation of mTOR are complex
and incompletely understood (Figure 1). Although various
pathways leading to mTORC1 activation have been described,
the precise upstream signals leading to mTORC2 activation
remain basically undefined (Laplante and Sabatini, 2009b). In a
general scheme, growth factor or cytokine signaling leads to
the activation of PI3-kinase which in turn leads to the activation
of phosphoinositide-dependent kinase 1 (PDK1), which then302 Immunity 33, September 24, 2010 ª2010 Elsevier Inc.promotes the phosphorylation of Akt at threonine 308. The prox-
imal activation motif phosphorylation of Akt leads to the phos-
phorylation and inactivation of tuberous sclerosis complex
(TSC). TSC (which is comprised of TSC1 and TSC2) functions
as a GTPase-activating protein (GAP) for the ras homolog
enriched in brain (Rheb). Rheb is a small GTPase that has been
shown to be a crucial regulator of mTORC1 signaling (Saucedo
et al., 2003; Yamagata et al., 1994; Yee and Worley, 1997).
When TSC is inhibited, the active, GTP-bound form of Rheb
interacts with mTORC1 to stimulate its activity (Manning and
Cantley, 2003). From the immunologist’s perspective notably,
the PI3K-Akt-mTORC1 axis is activated by CD28 engagement
and IL-2 receptor signaling (Colombetti et al., 2006). In addition,
IL-7 promotes mTOR activity, helping to prevent atrophy in
T cells (Rathmell et al., 2001). IL-4-induced mTOR activity has
been shown to promote proliferation and prevent apoptosis
through the PI3K-Akt axis (Cardoso et al., 2009; Stephenson
et al., 2005). Furthermore, IL-12 and IFN-g have also been shown
to promote the sustained activation of mTORC1 (Lekmine et al.,
2004; Rao et al., 2010). Finally, evidence is accumulating demon-
strating the ability of Wnt signaling to regulate mTORC1 activity
in a glycogen synthase kinase 3 (GSK3)-dependent fashion (Inoki
et al., 2006).
mTORC1 activity is profoundly regulated by amino acids,
especially leucine (Proud, 2007). When leucine is available
from the environment, it is transported in a glutamine-dependent
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has been shown that in the presence of leucine (and other amino
acids), Rag proteins (in this case a family of small GTPases, not
recombinases) bind to raptor and promote the interaction
between mTORC1 and Rheb (Sancak et al., 2008). During amino
acid deprivation, even potent upstream activators of Rheb fail to
activate mTOR. Mimicking leucine deficiency by using the
leucine antagonist N-acetyl-leucine-amide (NALA), our group
and others have been able to inhibit T cell function (Hidayat
et al., 2003; Zheng et al., 2009).
Energy status as determined by the ratio of intracellular ATP/
ADP also regulates mTORC1 activity. A paucity of ATP leads
to the activation of AMP-activated protein kinase (AMP-kinase)
that in turn inhibits mTORC1 activity by phosphorylating TSC2
and enhancing its GAP activity. As such, the AMP-kinase activa-
tors AICAR and the Type 2 diabetes drug metformin have both
been shown to affect T cell function (Nath et al., 2005; Pearce
et al., 2009).
Availability of oxygen can also regulate mTOR function. Under
minimally hypoxic conditions, there is a decrease in ATP leading
to AMP-kinase activity (Laplante and Sabatini, 2009b). Alterna-
tively, hypoxia can inhibit mTORC1 activity by enhancing the
expression of DNA damage response 1 (REDD1). REDD1 inhibits
mTORC1 by causing TSC2 to disassociate from 14-3-3 proteins
and enhancing its ability to block Rheb.
The diverse upstream activators of mTOR lead to equally
diverse downstream consequences. For example, in a T cell,
activating mTOR with insulin will not have the same functional
consequences as activating mTOR via CD28 (Sabatini, 2006;
Zheng et al., 2007). In this regard the list of downstream
substrates and pathways for mTOR is ever increasing. Typically
mTORC1 and mTORC2 activation is measured by phosphoryla-
tion of canonical substrates. mTORC1 activity can be monitored
by the phosphorylation of p70 ribosomal S6 kinase 1 (S6K1) or its
downstream substrate S6 as well as by the phosphorylation of
the translational inhibitor eukaryotic initiation factor 4E binding
protein 1 (4EBP-1) (Beugnet et al., 2003). A major role for
mTORC1 is to regulate protein translation. In addition, mTORC1
activation also serves to inhibit autophagy and promote lipid
metabolism and mitochondrial biogenesis (Laplante and Saba-
tini, 2009a). The net sum of these activities is to promote growth
and differentiation.
The archetypical indicator of mTORC2 activity is the phos-
phorylation of Akt at its hydrophobic motif, serine 473 (Bhaskar
and Hay, 2007). It is clear from this observation that Akt phos-
phorylation is both upstream and downstream of mTOR. Activa-
tion of mTORC1 by Akt (as indicated by phosphorylation of
threonine 308) is not dependent upon mTORC2-mediated acti-
vation of Akt (as indicated by phosphorylation of serine 473).
In general, mTORC2-dependent Akt activity positively regulates
processes that promote proliferation and survival. In addition,
Akt promotes the phosphorylation of the transcription factors
Forkhead box O1 (Foxo1) and Foxo3a, leading to their exclusion
from the nucleus and hence their inactivation (Laplante and
Sabatini, 2009b). Another mTORC2 substrate, the serum and
glucocorticoid-induced protein kinase 1 (SGK1), is also involved
in the regulation of the Foxo family of transcription factors
(Huang et al., 2009). Finally, mTORC2 activation has been impli-
cated in promoting cytoskeletal reorganization. This is believedto be mediated by the ability of mTORC2 to promote the phos-
phorylation and hence activation of protein kinase C alpha
(PKC-a) (Ikenoue et al., 2008).
T Cell Responses Are Metabolically Demanding
The metabolic demands of T cells are extraordinary, rivaling that
of cancer cells (Fox et al., 2005). As a consequence, T cell
metabolism is highly regulated. However, it is not that T cell acti-
vation leads to an upregulation in metabolism; rather, an
increase in the metabolic machinery is an integral component
of T cell activation (Jones and Thompson, 2007). Quiescence
in T cells is an actively maintained state (Berger et al., 2010;
Buckley et al., 2001; Modiano et al., 2008). A number of mole-
cules including Schlafen-2 (Slfn2), transducer of ERB2 1
(TOB1), Kru¨ppel-like factor 2 or lung Kru¨ppel-like factor (KLF2
or LKLF), and Foxos have all been implicated in actively sup-
pressing T cell function by promoting the expression of inhibitors
of activation. Both KLF2 (LKLF) and Foxo have also been impli-
cated in regulating metabolism. The resting state is character-
ized metabolically by catabolism. Quiescent T cells employ au-
tophagy to derive molecules necessary for energy and baseline
protein synthesis.
Upon activation there is a switch from catabolism to anabolism
(Fox et al., 2005; Jones and Thompson, 2007). In spite of
adequate amounts of oxygen in the environment, T cells employ
glycolysis to generate energy. This state of oxidative glycolysis is
known as the Warburg effect and is also employed by cancer
cells. At first, it seems counterintuitive that cells that have
markedly increased their demand for energy would employ
a relatively inefficient means to generate ATP. To answer this
question, Thompson has proposed that whereas glycolysis is
less efficient in generating ATP, the glycolytic pathway provides
substrates for the generation of amino acids, nucleotides, and
lipids (Vander Heiden et al., 2009). T cells can afford to ineffi-
ciently produce ATP because essentially ATP is not limiting.
However, T cell activation demands adequate amounts of the
essential components for protein, lipid, and DNA biosynthesis.
mTOR plays a critical role in regulating these processes. It is
within this context that an essential component of T cell activa-
tion is the upregulation of the metabolic machinery supporting
these events. Whereas a critical function of CD28-mediated
costimulation is to promote the generation of IL-2, an equally
important aspect of costimulation is to promote the metabolic
machinery necessary to support T cell activation (Frauwirth
et al., 2002; Frauwirth and Thompson, 2004). Along these lines,
Th1 cells rendered anergic (with TCR stimulation alone) fail to
express IL-2 upon rechallenge with TCR and CD28 stimulation
(Zheng et al., 2009). Likewise, anergic T cells cannot fully activate
mTOR when rechallenged, and fail to fully upregulate the
metabolic machinery required for glucose transport, protein,
and lipid synthesis. Based on these observations, one might
speculate that the inability of anergic T cells to become
metabolically active plays a role in maintaining the state of
T cell anergy.
In light of the robust metabolic demands of T cell activation,
it is not surprising that regulation of T cell activation can be
achieved by limiting nutrient availability. The work of Mellor
and Munn and subsequently others has shown the ability of
tryptophan availability to inhibit immune responses (MellorImmunity 33, September 24, 2010 ª2010 Elsevier Inc. 303
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Reviewand Munn, 2004). The precise role if any of mTOR in tryptophan-
mediated regulation of T cell function remains unknown.
Recently, it has been shown that not only is glutamine required
for T cell function, but glutamine uptake is increased with
CD28 signaling (Carr et al., 2010). In addition, the ability of
leucine to regulate T cell function is emerging. The leucine analog
NALA can inhibit T cell function, and TCR engagement in the
presence of NALA promotes T cell anergy (Hidayat et al., 2003;
Zheng et al., 2009). Inasmuch as a lack of leucine inhibits
mTORC1 activation, these latter findings are consistent with
the observations that TCR engagement in the absence of
mTOR activity promotes anergy (Powell et al., 1999). Similarly,
glucose analogs that block metabolism have also been shown
to block T cell function (Cham et al., 2008). As is the case with
NALA, the glucose analog 2-deoxyglucose (2DG) can inhibit
mTOR function (most likely via the AMP-kinase pathway) and
thus promote anergy. Finally, the AMP-kinase activator AICAR,
bymimicking energy depletion, can acutely inhibit T cell function,
mitigate experimental autoimmune encephalomyelitis, and
promote anergy by inhibiting mTOR (Jhun et al., 2005; Nath
et al., 2005; Zheng et al., 2009). More recently, it has been shown
that another AMP-kinase activator, metformin, can promote
CD8+ memory T cell development (discussed in more detail
below) (Pearce et al., 2009).
The precise role that regulation of nutrient availability plays in
controlling mTOR under natural circumstances remains to be
determined. Modulation of T cell function by regulating trypto-
phan and cysteine concentrations has already been described
(Angelini et al., 2002; Mellor and Munn, 2004). Recently, it has
been shown that regulatory T cells can inhibit T cell function by
expressing enzymes that deplete the environment of essential
amino acids (Cobbold et al., 2009). The depletion of amino acids
in turn leads to the inhibition of mTOR in target T cells that in turn
leads to the upregulation of the transcription factor Foxp3. Like-
wise, one might predict that mechanisms regulating mTOR by
controlling glutamine, leucine, glucose, and energy availability
will also be revealed.
Signal 1 in the Absence of mTOR Activation Leads
to Anergy in Th1 Cells
When CD4+ Th1 T cells recognize antigen through their TCR
(signal 1) in the absence of costimulation (signal 2), they are
rendered anergic (Schwartz, 2003). That is, such cells will fail
to vigorously proliferate and produce IL-2 upon subsequent
rechallenge with full (signal 1 + 2) stimulation. (In this section
we refer to signal 2 as described by Lafferty and Cunningham
[1975], that is, a ‘‘second’’ APC-derived signal that is required
for the full activation of a T cell. Later on in this reviewwe propose
that the scope of signal 2 be broadened with mTOR as a central
integrator of its function.) Our laboratory and others demon-
strated that anergy could be induced even in the presence of
costimulation (for example, CD28 engagement) if the mTOR
inhibitor rapamycin was present during TCR engagement
(Powell et al., 1999; Vanasek et al., 2001). Originally, it was
thought that rapamycin promoted anergy by inhibiting cell cycle
progression, thus preventing the dilution of regulatory ‘‘anergic
factors’’ (Jenkins, 1992). However, it became clear that it was
not cell cycle progression that prevented anergy but rather the
activation of mTOR itself (Allen et al., 2004; Colombetti et al.,304 Immunity 33, September 24, 2010 ª2010 Elsevier Inc.2002; Zheng et al., 2007). For example, both rapamycin and
sanglifehrin A inhibit T cell proliferation in G1. However, in spite
of its ability to block proliferation, sanglifehrin A does not
promote T cell anergy. For CD4+ Th1 cells, TCR engagement in
the absence of mTOR activation leads to anergy. Such findings
suggested that mTOR was a biochemical tranducer of signal 2.
In other words, just as mTOR plays a role in interrogating the
environment for nutrient status, mTOR also senses the immune
microenvironment for ‘‘danger signals’’ in T cells. Such signals,
transmitted through the presence of costimulatory molecules,
tell the T cell that antigen recognition should promote activation.
In the absence of such signals (hence, a lack of mTOR activa-
tion), recognition leads to tolerance. As mentioned above,
subsequent studies have revealed that, in addition to rapamycin,
blocking metabolic pathways necessary for mTOR activation
can also promote the induction of anergy (Zheng et al., 2009).
Teleologically, the necessity of mTOR activation to promote
Th1 effector cell responses makes sense; the metabolic
demands of such a response require mTOR activation.
mTOR Senses the Immune Microenvironment to Direct
CD4+ T Cell Differentiation
The ultimate fate of a naive T cell is dictated by multiple cues
from the immune microenvironment (Bettelli et al., 2007). Naive
CD4+ T cells activated in the presence of IFN-g and IL-12
develop into Th1 effector cells, whereas CD4+ T cells stimulated
in the presence of IL-4 are fated to become Th2 effector cells.
CD4+ T cells stimulated in the presence of IL-6 and TGF-b differ-
entiate into IL-17-producing Th17 cells. Further, when naive
CD4+ T cells are stimulated in the presence of high concentra-
tions of TGF-b, they do not become effector cells but rather
Foxp3+ regulatory T cells (Chen et al., 2003). In vitro, differentia-
tion into these T cell subsets is easily achieved by culturing cells
in high concentrations of cytokines and cytokine-neutralizing
antibodies. However, in vivo, differentiation results from simulta-
neous integration of multiple, even opposing, signals.
Having previously demonstrated that mTOR played a role in
promoting effector function in Th1 cells, our group hypothesized
that mTORmight also play a role in promoting the transition from
naive to effector CD4+ T cells (Delgoffe et al., 2009). To test this
hypothesis we created mice in which mTOR was deleted in
T cells. Indeed, the mTOR-deficient T cells failed to become
Th1, Th2, or Th17 effector cells when stimulated under appro-
priate skewing conditions both in vitro and in vivo. Along these
lines, it has recently been shown that rictor-deficient T cells
display an inability to become Th2 cells and a diminished
capacity to become Th1 cells (Lee et al., 2010). By targeting
Rheb in T cells, our lab has observed that Th1 and Th17 cell
differentiation but not Th2 cell differentiation is mTORC1 depen-
dent (unpublished findings). Likewise, we find that rictor-defi-
cient T cells fail to develop into Th2 cells; however, in contrast
to the work of Lee et al., we find no defect in Th1 cell differenti-
ation in the rictor null T cells (Lee et al., 2010). At this point it is
unclear whether mTORC1 and mTORC2 are differentially
activated during Th1 and Th2 cell differentiation. For example,
it may be that mTORC1 is equally activated under Th1 and
Th2 cell conditions but that under Th1 cell conditions, spe-
cific Th1 cell-promoting mTORC1-dependent substrates are
expressed. Overall, given that the activation of naive CD4+
Figure 2. Linking Metabolism and mTOR
Activity
Quiescence in T cells is an active state that is
maintained by Slfn2, Foxo transcription factors,
TOB, and KLF2. Naive T cells are catabolic and
have low levels of mTOR activity. Activation and
effector generation for both CD4+ and CD8+
T cells results in tremendous metabolic demands
and a switch from catabolism to anabolism (right).
By necessity mTOR activity is high, which not only
supports this increase in metabolism but also
promotes both CD8+ and CD4+ effector T cell
generation. Alternatively, inhibition of mTOR in
CD8+ T cells promotes the generation of memory
cells. Such cells are characterized by low meta-
bolic demands, low mTOR activity, and an
increase in the Foxo transcription factors, KLF2,
and eomesodermin. Likewise, activation in the
context of mTOR inhibition promotes the genera-
tion of regulatory T cells. These cells, which are
less metabolically demanding than their effector
counterparts, display decreased mTOR activity
but increased Pim2 kinase activity.
Immunity
ReviewT cells is metabolically demanding, it seems logical that effector
differentiation cannot occur in the absence of mTOR activation
(Figure 2).
Mechanistically, the inability to become effector cells in the
mTOR null T cell mice was associated with a failure to upregulate
appropriate effector-specific transcription factors (Delgoffe
et al., 2009). That is, the mTOR null T cells failed to upregulate
sustained expression of T-bet in Th1 cells, GATA-3 in Th2 cells,
and RORgt in Th17 cells. This decrease in the upregulation of
T cell-specific transcription factors was seen in the setting of
decreased STAT activation in response to skewing cytokines.
The precise role that mTOR plays in terms of regulating STAT
activation in T cells still remains to be determined. However, links
between mTOR and STAT signaling have been indentified in
cancer cells, where for example, it has been shown that mTOR
activation can promote STAT3 phosphorylation (Ma et al.,
2010). Because STAT activation was not eliminated but rather
diminished in the mTOR null T cells, it is likely that this effect
contributes to but is not the sole mechanism accounting for
the inability of such cells to differentiate into CD4+ effector cells.
Along these lines recent findings suggest that mTORC2
activation of PKC-q contributes to Th2 cell differentiation (Lee
et al., 2010).
In the absence of mTOR, naive CD4+ T cells differentiate into
Foxp3+ regulatory T cells (Delgoffe et al., 2009). That is, under
normally effector skewing conditions, full T cell activation in the
absence of mTOR leads to a default regulatory T cell pathway.
Interestingly, whereas the generation of regulatory cells occurs
in the absence of exogenous TGF-b, the mTOR null T cells
displayed constitutively phosphorylated SMAD3 and neutraliza-
tion of TGF-b diminishes the generation of Foxp3+ cells. These
observations suggest that basal TGF-b signaling, unopposed
by mTOR activation, can drive regulatory cell differentiation.
Consistent with the findings employingmTOR-deficient T cells
are the observations that rapamycin can promote the generation
of regulatory T cells both in vitro and in vivo (Battaglia et al., 2005;
Kang et al., 2008; Kopf et al., 2007). Rapamcyin-induced regula-
tory T cell generation is associated with histone H3K4me2 and 3
methylation near the Foxp3 transcriptional start site (Sauer et al.,2008). Alternatively, activation of the Akt-mTOR axis by the
expression of a constitutively active Akt impairs the generation
of CD4+ Foxp3+ T cells in the thymus (Haxhinasto et al., 2008).
In the periphery, it appears as if PD-L1 on the surface of
antigen-presenting cells can promote the development, mainte-
nance, and function of inducible regulatory T cells in part by
inhibiting mTOR activation in T cells (Francisco et al., 2009).
Initially, it was thought that rapamycin specifically inhibited
mTORC1 without affecting mTORC2 activity. As such, the ability
of rapamycin to promote Treg cell generation was ascribed to its
ability to inhibit mTORC1. However, studies in several different
cell lines have demonstrated the ability of rapamycin to inhibit
mTORC2 (Sarbassov et al., 2006). Our own group has noted
that in primary T cells, rapamycin at doses as low as 20 nM
can inhibit both mTORC1 and mTORC2 activity (unpublished
findings). Along these lines, the genetic deletion of mTORC1
activity or mTORC2 activity alone has been shown to be insuffi-
cient to promote Treg cell differentiation (Delgoffe et al., 2009;
Lee et al., 2010). Furthermore, more recently, focus has been
placed on the role of Foxo1 and Foxo3a on regulating Foxp3
expression (Harada et al., 2010; Merkenschlager and von
Boehmer, 2010; Ouyang et al., 2010). Recall that mTORC2-
dependent phosphorylation of Foxo1 and Foxo3a leads to inac-
tivation by promoting their sequestration in the cytoplasm (Lap-
lante and Sabatini, 2009b). Both of these transcription factors
have been shown to play a role in Foxp3 expression. Thus, in
the presence of mTORC2 activation, Foxo1- and Foxo3a-medi-
ated Foxp3 expression is diminished.
When examining the link between T cell activation and metab-
olism, the observation that mTOR inhibition promotes regulatory
T cell generation is quite logical (Figure 2). The metabolic
demands of regulatory T cells appear to be much less than
that of conventional CD4+ T cells. As a consequence, regulatory
T cells are less dependent on mTOR activation for their function.
Regulatory T cells thus have an advantage in terms of signaling,
survival, and proliferation in the presence of rapamycin when
compared to conventional T cells (Strauss et al., 2009; Zeiser
et al., 2008). It is thought that this relative resistance to rapamy-
cin in regulatory T cells is imparted by an upregulation of Pim 2Immunity 33, September 24, 2010 ª2010 Elsevier Inc. 305
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that shares many functions with Akt and is not inhibited by rapa-
mycin. Rather, Pim 2 expression is increased when mTOR is
inhibited. Further, the increased expression of Pim 2 appears
to be mediated by Foxp3.
The ability of mTOR inhibition to inhibit CD4+ T cell effector
differentiation and promote the generation of regulatory T cells
has important clinical implications for transplantation and the
treatment of autoimmune diseases. The ability to generate
Foxp3+ regulatory cells from diabetes patients by ex vivo activa-
tion in the presence of rapamycin has been established (Batta-
glia et al., 2006; Putnam et al., 2009). Efforts are under way to
generate ex vivo regulatory T cells to modulate graft versus
host disease (GVHD) (Golovina et al., 2008). The Fowler lab
has published a series of studies demonstrating the ability of
rapamycin to promote Tc2 and Th2 cells ex vivo which, when
infused into mice undergoing bone marrow transplantation,
abrogate GVHD (Foley et al., 2005; Jung et al., 2006). It is not
precisely clear why their culture conditions favor the generation
of Tc2 and Th2 cells in the presence of rapamycin. As previously
mentioned, depending on the dose and duration of exposure
in vitro, rapamycin can either specifically inhibit mTORC1 alone
or inhibit both mTORC1 and mTORC2. As such it may be that
these specific culture conditions favor a preferential inhibition
of mTORC1 without inhibiting mTORC2.
The results of the use of rapamycin as an immunosuppressive
agent in transplantation have not been as spectacular as one
might have predicted based on the animal studies. This may
be due to the fact that rapamycin does not acutely inhibit inflam-
mation (Saemann et al., 2009). Clinically, often mTOR inhibitors
had been employed in conjunction with calcineurin inhibitors
(CSA and FK506), which will completely block the tolerance
promoting abilities of mTOR inhibitors (Powell and Zheng,
2006). To avoid this pitfall, we employed the mTOR inhibitor siro-
limus with CAMPATH and nonmyeloablative doses of total body
irradiation in a matched sibling hematopoieitic stem cell trans-
plant setting for the treatment of sickle cell disease. With this
regimen (which did not block TCR signaling with a calcineurin
inhibitor), we were able to generate persistent mixed chimerism
(Hsieh et al., 2009). In this regard, others have also employed
mTOR inhibitors in the absence of calcineurin inhibitors in an
effort to promote long-lasting transplant tolerance (Swanson
et al., 2002).
mTOR Inhibition Promotes the Development of CD8+
T Cell Memory
Upon initial infection there is a tremendous increase in the
frequency of antigen-specific effector cells (Araki et al., 2010).
This expansion is followed after 2 weeks by a contraction phase
and then the maintenance of a pool of antigen-specific memory
cells poised to rapidly respond upon rechallenge. Overall, this
process is characterized by an increase in the cell surface
expression of the IL-7 receptor (CD127), the re-expression of
CD62L, and an increase in the antiapoptotic molecule Bcl2.
The progressive increase in CD62L and CCR7, CD127, and
Bcl-2 all seem to be associated with increased properties of
self-renewing memory cells. Although the precise molecular
details regulating the development of CD8+ T cell memory
have yet to be determined, the transcription factors T-bet and306 Immunity 33, September 24, 2010 ª2010 Elsevier Inc.Eomesodermin appear to play important roles (Intlekofer et al.,
2005). During the initiation of the acute response, sustained
T-bet expression, maintained by IL-12, drives the generation of
effector cells (Joshi et al., 2007). IL-12 also serves to inhibit
eomesodermin, which is thought to promote the effector to
memory transition (Takemoto et al., 2006). As inflammation
subsides, IL-12 expression decreases, leading to an increase
in eomesodermin, thus supporting memory cell development.
From a metabolic perspective, the massive expansion of
antigen-specific effector cells from the naive T cell pool requires
much energy and is characterized by increased protein, lipid,
and nucleotide synthesis (Figure 2; Pearce, 2010). As with
CD4+ T cells, mTOR plays a central role in facilitating the
anabolic processes that facilitate CD8+ effector generation.
Alternatively, as antigen is cleared and there is a switch to the
development of long-lived memory cells, metabolism switches
back to catabolism.
Recently there has been a series of reports describing the
ability of rapamycin to enhance the generation of memory
T cells. Araki et al. infected mice with lymphocytic choriomenin-
gitis virus (LCMV) and found that treatment with rapamycin led to
an increase in antigen-specific CD8+ T memory cells (Araki et al.,
2009). Specifically, treatment of mice during the expansion
phase (days 0–8) led to an increase in memory cells. This was
reported to be due to a decrease in the contraction of the
antigen-specific cells. Additionally, treatment of mice during
the contraction phase (days 8–30) seemed to accelerate the
effector to memory cell transition and led to the development
of more robust memory cells. Importantly, the dose of rapamycin
used in these studies was suboptimal with regard to mTOR
inhibition; higher doses of rapamycin resulted in suppression
of CD8+ T cell expansion. Nonetheless, the effect appeared to
be T cell intrinsic and dependent on mTORC1 signaling. Gene
targeting raptor in the antigen-specific CD8+ T cells reproduced
the results obtained with low-dose rapamycin treatment.
Further, gene targeting the binding partner of rapamycin
FK506 binding protein 12 (FKBP12) in the antigen-specific
CD8+ T cells abrogated the ability of rapamycin to promote
memory cell development.
In a separate report, Rao et al. also demonstrated the ability of
rapamycin to enhance the generation of CD8+ memory cells.
In their model, IL-12 led to the sustained activation of mTOR
and the upregulation of T-bet (Rao et al., 2010). This promoted
the generation of effector T cells. The presence of rapamycin
inhibited mTOR activity, leading to a decrease in T-bet and
a subsequent increase in eomesodermin that in turn promoted
the generation of memory T cells. A third study has also demon-
strated the ability of mTOR inhibition as a means of enhancing
the generation of CD8+ memory T cells (Pearce et al., 2009).
In this report it was noted that TNF receptor-associated factor
6 (TRAF6)-deficient T cells became effector cells but failed to
generate memory T cells. This defect was associated with
a failure to switch to catabolism with regard to fatty acid oxida-
tion (FAO). AMP-kinase is an important regulator of FAO.
It was noted that the TRAF6-deficient CD8+ T cells had lower
amounts of AMP-kinase activity upon growth factor withdrawal.
By treating such cells with the AMP-kinase activator metformin,
this defect could be overcome and the ability of such cells to
become memory cells restored. Not only did the metformin
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case with the previous two studies, the addition of rapamycin
could also enhance the induction of memory cells. Our own
unpublished studies examining naive CD8+ T cells lacking
mTORC1 signaling demonstrate that in vitro such cells prolif-
erate more slowly and have decreased expression of effector
cell markers but more readily upregulate memory markers.
Thus, for both naive CD4+ and CD8+ T cells, mTOR plays
a role in regulating effector function. Inhibition of mTOR in naive
CD4+ T cells promotes the generation of regulatory T cells
whereas inhibition of mTOR in naive CD8+ T cells promotes the
generation of memory T cells. Although functionally regulatory
T cells and memory cells are quite diverse, metabolically, their
demands seem similar.
Inasmuch as rapamycin is an immunosuppressive agent, at
first glance it seems somewhat paradoxical that the inhibition
of mTOR would promote immunity in the form of T cell memory.
However, in the context of the metabolic demands of T cell
effector function, such observations makemore biological sense
(Figure 2). Furthermore, these observations have potential
clinical implications. Overall these findings suggest that the stra-
tegic inhibition of mTOR might enhance the development of
memory cells in response to vaccines. Testing their findings in
nonhuman primates, Araki et al. were able to demonstrate that
rapamycin treatment enhanced memory responses to vaccinia
virus (Araki et al., 2009). Likewise, others have shown that rapa-
mycin and metformin can enhance antitumor responses in
mouse models (Pearce et al., 2009; Rao et al., 2010).
The Role of mTOR in Regulating T Cell Trafficking
Trafficking of T cells to secondary lymphoid organs and tissues is
intimately related to the functional state of the T cell. For CD8+
T cells, the cell surface markers that are employed to identify
naive, effector, and memory T cells such as CD44, CD62L, and
CCR7 are involved in controlling T cell migration (Finlay and
Cantrell, 2010). Naive T cells express CD62L and CCR7, which
facilitates their trafficking between secondary lymphoid organs.
Upon T cell activation, these receptors are downmodulated and
other receptors are upregulated, facilitating their redirection to
inflamed tissues. From a metabolic perspective, catabolic naive
cells downregulate CD62L and CCR7 as they become anabolic.
This process is regulated by the PI3-kinase-mTOR axis. Deletion
of PTEN in CD8+ T cells that leads to increased PI3-kinase
activity results in the loss of expression of CD62L and CCR7
(Sinclair et al., 2008). Alternatively, treatment with rapamycin
prevents the downregulation of thesemolecules upon activation.
The transcription factor KLF2 promotes the transcription of both
CD62L and CCR7. KLF2 expression is promoted by Foxo1
(Fabre et al., 2008; Kerdiles et al., 2009). Thus, upon mTOR acti-
vation, Foxo1 is sequestered in the cytoplasm, leading to
decreased KLF2 expression and subsequent decreased tran-
scription of CD62L and CCR7. As an infection is cleared and
T cell activation (and metabolic demands) decreases, mTOR
activity decreases, leading to re-expression of these cell surface
markers. As such these newly formed memory cells display cell
surface markers that promote their trafficking throughout
secondary lymphoid tissues.
The G protein-coupled receptor Sphingosine 1-phosphate
receptor 1 (S1P1) is also regulated in this fashion (Carlsonet al., 2006). S1P1 promotes egress from lymph nodes through
ligation of its natural receptor sphingosine 1-phosphate (Matlou-
bian et al., 2004). S1P1 null T cells fail to leave the thymus while
S1P1 transgenic T cells fail to traffic efficiently to lymphoid
organs. Recently, a role for S1P1 in modulating regulatory
T cell development and function has emerged (Liu et al., 2009).
Transgenic expression of S1P1 inhibits the development of regu-
latory T cells as well as impairs the ability of Foxp3+ cells to
suppress. Interestingly, this ability to block Treg cell develop-
ment and function was associated with the induction of mTOR
activity. That is, rapamycin prevented the ability of S1P1 to
mitigate Treg cell function. Thus, inhibition of mTOR promotes
the generation of regulatory T cells and regulatory T cells display
decreased mTOR activity. The S1P1 is upregulated by mTOR
inhibition but signaling by S1P leads to increased mTOR activa-
tion and consequently decreased regulatory T cell function.
From the perspective of the naive T cell, antigen activation
greatly increases the metabolic demands of the cell. In part,
this demand can be facilitated by increased mTOR activation
induced by S1P as the cell begins its egress from the lymph
node. However, this activation in turn downmodulates S1P1
(as well as CD62L and CCR7), allowing for the cells to traffic to
the sites of inflammation.
Redefining Signal 2
The adaptive immune response is characterized by the remark-
able antigen receptor diversity (and thus, specificity). It is also
characterized by the ability to develop robust initial responses
and rapid recall responses. A consequence of these functions
is the fact that T cell activation encumbers prodigious metabolic
demands. The stochastic generation of antigen receptors neces-
sitates accessory signals derived from the environment to guide
lymphocyte activation. The two-signal model provides a frame-
work for understanding how TCR recognition leads to appro-
priate T cell activation or tolerance. Antigen recognition through
the TCR (signal 1) in the presence of ‘‘danger’’ or ‘‘infectious
nonself’’ signals (signal 2) promotes activation whereas signal 1
alone leads to tolerance (Fuchs and Matzinger, 1996; Medzhitov
and Janeway, 2000). However, the consequences of antigen
recognition are not simply activation versus tolerance. Rather,
for both CD4+ and CD8+ T cells, TCR engagement in the context
of specific environmental cues can lead to the generation of
a diverse array of effector, regulatory, and memory cells.
Although the term signal 3 has been used to refer to signaling
derived from inflammatory cytokines, one might also think of
signal 2 as the net sum of both activating and inhibitory signals
derived from the inflammatory milieu. We propose to expand
the role of signal 2 to not only dictate activation versus tolerance
but also to direct differentiation. In our model, signal 1 heralds
antigen recognition whereas signal 2 refers to the integrated
sum of environmental cues. We propose that mTOR serves to
integrate costimulatory, cytokine, nutritional, and energetic envi-
ronmental cues to dictate the course of T cell differentiation and
function upon antigen recognition (Figure 3). TCR signaling
(recognition) leads to activation of multiple signaling pathways
(for example, AP-1, NF-AT, and NF-kB), which in turn leads to
the transcription of a large number of genes (Riley et al., 2002).
TCR engagement leads to the expression of numerous mole-
cules associated with activation (for example cytokines andImmunity 33, September 24, 2010 ª2010 Elsevier Inc. 307
Figure 3. Redefining Signal 2
Signal 1 refers to antigen recognition through the TCR and is characterized by
the transcription of many genes. The outcome of this recognition is dictated by
the net sum of environmental signals (signal 2). We propose that mTOR acts to
integrate all of these signals which in turn direct the outcome of T cell differen-
tiation and activation.
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tory molecules such as Cbl-b. Likewise, even under specific
effector skewing conditions upon initial stimulation, naive
T cells might express multiple T cell-specific transcription
factors. For example, in response to activation in the presence
of TGF-b, naive T cells can coexpress Foxp3 and ROR-gt (Lee
et al., 2009). Signal 2, which we define as the net sum of environ-
mental cues, will dictate the ultimate outcome of recognition.
mTOR plays a central role in integrating these environmental
cues to direct T cell activation and differentiation. For example,
during inflammation under Th17 cell skewing conditions,
Foxp3 expression will become extinguished and the cells will
differentiate into Th17 effector cells. Alternatively, strong PD-1
engagement might tip the balance in favor of regulatory T cell
development by inhibiting mTOR. Likewise, although a precise
connection between mTOR and CTLA-4 has not been defined,
CTLA-4 has been shown to mediate its effects in part by acti-
vating the phosphatase PP2A, which has been shown to be
inhibited by mTOR (Chuang et al., 2000; Peterson et al., 1999).Concluding Remarks
The ability of mTOR activation to enhance or inhibit T cell differ-
entiation and function is intimately linked to the metabolic
demands of the T cell. Future studies will seek to determine
the precise pathways leading from mTOR to T cell function. In
this regard, the ability of mTOR signaling to regulate the Foxo
family of transcription factors has provided several incisive links
(Merkenschlager and von Boehmer, 2010). Identification of addi-
tional downstream substrates and pathways of mTORC1 and
mTORC2 should provide important insight in terms of how
mTOR regulates specific effector, memory, or regulatory T cell308 Immunity 33, September 24, 2010 ª2010 Elsevier Inc.differentiation. Further, elucidating additional roles for mTOR
signaling in T cells will enhance our understanding and ability
to manipulate T cell responses to infection, in autoimmunity,
and posttransplantation.ACKNOWLEDGMENTS
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